Results 271 to 280 of about 47,200 (309)

Prior Anticoagulation and Risk of Hemorrhagic Transformation in Acute Stroke: A Post Hoc Analysis of the PRODAST Study. [PDF]

J Am Heart Assoc
Grosse GM, Hüsing A, Stang A, Kuklik N, Brinkmann M, Grond M, Rollnik JD, Marquardt L, Kraft A, Schlemm E, Eggers C, Eschenfelder CC, Weimar C, Diener HC.   +13 more
europepmc   +1 more source

Population pharmacokinetic study of the effect of polymorphisms in the ABCB1 and CES1 genes on the pharmacokinetics of dabigatran. [PDF]

Front Pharmacol
Yang Z, Tan WR, Li Q, Wang Y, Liu S, Chen L, Zhou Y, Zeng C, Zeng Y, Xiong Y, Zhang Q, Li N, Du P, Liu L, Chen J, He Y.   +15 more
europepmc   +1 more source

The trouble with dabigatran [PDF]

BMJ, 2014
Doctors and patients must tread carefully through emerging risks Options for stroke prevention in high risk non-valvular atrial fibrillation have recently broadened with the addition of new oral anticoagulants as an alternative to warfarin, the traditional and effective treatment.
Blake Charlton, Rita F. Redberg
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—Updated series of 120 cases

International Journal of Stroke, 2020
Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for ...
P. Kermer, C. Eschenfelder, H. Diener, M. Grond, Y. Abdalla, Alexej Abraham, K. Althaus, Gebhard Becks, J. Berrouschot, Jörg Berthel, F. Bode, L. Burghaus, H. Cangür, M. Daffertshofer, Sebastian Edelbusch, J. Eggers, R. Gerlach, K. Gröschel, F. Grosse-Dresselhaus, A. Günther, C. Haase, C. Haensch, A. Harloff, J. Heckmann, V. Held, M. Hieber, A. Kauert, R. Kern, T. Kerz, M. Köhrmann, P. Kraft, P. Kühnlein, J. Latta, E. Leinisch, Arne Lenz, C. Leithner, T. Neumann-Haefelin, M. Mäurer, W. Müllges, C. Nolte, M. Obermann, S. Partowi, Peer Patzschke, S. Poli, U. Pulkowski, J. Purrucker, T. Rehfeldt, P. Ringleb, J. Röther, ra Rossi, Hazem El-Sabassy, O. Sauer, G. Schackert, N. Schäfer, P. Schellinger, Andreas Schneider, R. Schuppner, S. Schwab, Olav Schwarte, R. Seitz, S. Senger, Y. Shah, E. Sindern, P. Sparenberg, T. Steiner, K. Szabo, C. Urbanek, Bettina von Sarnowksi, K. Weissenborn, P. Wienecke, K. Witt, Robert Wruck, S. Wunderlich   +72 more
semanticscholar   +1 more source

Dabigatran Etexilate

Drugs, 2008
Dabigatran etexilate is an orally administered prodrug of dabigatran, which is a potent, concentration-dependent inhibitor of thrombus formation and thrombin-induced platelet aggregation. Dabigatran etexilate pharmacokinetics were linear across a wide dosage range.
Greg L. Plosker, Mark Sanford
openaire   +3 more sources

Dabigatran, bleeding, and the regulators [PDF]

BMJ, 2014
Thomas J Moore and colleagues highlight the differences in how US and European regulators managed the safety problems of the new anticoagulant dabigatran and ask both to think again and mandate plasma monitoring of ...
Donald R. Mattison, Thomas J. Moore, Michael R. Cohen   +2 more
openaire   +2 more sources

Dabigatran/Dabigatran etexilate

Drugs of the Future, 2005
Because of the crucial role of thrombin in the coagulation cascade and platelet activation, the enzyme is a primary target for the development of anticoagulant and antithrombotic drugs. The peptidomimetic dabigatran and its oral double prodrug dabigatran etexilate are univalent direct thrombin inhibitors.
J. Castaner, J. Bozzo, L. A. Sorbera
openaire   +2 more sources

Stroke reperfusion therapy following dabigatran reversal with idarucizumab in a national cohort

Neurology, 2020
Objective To assess the frequency and utilization trends of dabigatran reversal with idarucizumab and compare associated complications, outcomes, and door-to-needle times to those of patients not exposed to idarucizumab in a nationwide cohort of ...
P. A. Barber, Teddy Y. Wu, A. Ranta
semanticscholar   +1 more source